benitec.com - תחזית צמיחת רווחים לשנה הבאה BNTC

Benitec Biopharma Inc. (BNTC) competes in the DNA silencing niche, leveraging the uniqueness of the BB-301 system. Research centers in the US and Australia focus on treating genetic pathologies, while the strategy is based on completing trials for a muscular dystrophy drug. This chart, provided by the GURU.Markets platform, shows that the projection of the company's EPS for the next year demonstrates the fresh parameter -22.40.

Benitec Biopharma Inc. (BNTC) gene therapy development is independent of macroeconomic cycles and GDP, relying exclusively on medical research results. The projected net income growth rate per share reflects the analysts' consensus estimate regarding the future profitability of the business. This indicator measures the expected percentage change in EPS, allowing for the differentiation of fundamental growth from speculative overheating. Such securities belong to a high-risk asset class with potential for exponential growth.